Abstract
Rare diseases, also known as orphan diseases, are diseases with low occurrence in the population. Developing orphan drugs is challenging because of inadequate financial and scientific resources and insufficient subjects to run clinical trials. With advances in genome sequencing technologies, emergence of cell and gene therapies, and the latest developments in regulatory pathways, some orphan drugs that have curative potential have been approved. In India, due to its large population and resource crunch, developing orphan drugs is phenomenally challenging. After adopting the Orphan Drug Act, the US-FDA has continuously made advances in regulatory pathways for orphan drugs. Particularly, n-of-one clinical trials have been successful in some cases. India has recently adopted policies that have impacted the long-neglected rare-disease ecosystem; however, there is no clear regulatory path for orphan drug development in India. We have proposed a multi-pronged approach involving close collaboration between the government, regulatory bodies, industries, and patient advocacy groups to boost orphan drug development in India. We believe that rapidly evolving technologies and business models can enable better and faster development of novel orphan drugs in India and other resource-constrained countries.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrahamyan L, Feldman BM, Tomlinson G, et al. 2016 Alternative designs for clinical trials in rare diseases. Am. J. Med. Genet. C Semin. Med. Genet. 172 313–331
Al-Chalabi A and Hardiman O 2013 The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 9 617–628
Asher DR, Thapa K, Dharia SD, et al. 2020 Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin. Biol. Ther. 20 263–274
CDSCO 2019 New drugs and clinical trials rule. The Gazette of India (https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf)
Chakraborty M, Choudhury MC, Chakraborty I, et al. 2022 Rare disease patients in India are rarely involved in international orphan drug trials. PLoS Glob. Public Health 2 e0000890
Cheung K and Mitsumoto H 2022 Evaluating personalized (n-of-1) trials in rare diseases: how much experimentation is enough? (Harv: Data Sci. Rev) https://doi.org/10.1162/99608f92.e11adff0
Choudhury MC and Saberwal G 2019 The role of patient organizations in the rare disease ecosystem in India: an interview based study. Orphanet J. Rare Dis. 14 117
Ciszewski P 2023 Orphan drugs: PDUFA dates and FDA approvals (https://checkrare.com/2023-orphan-drugs-pdufa-dates-and-fda-approvals/)
Davies N 2023 Orphan Drugs: 2022 Thepharmaletter (https://www.thepharmaletter.com/article/orphan-drugs-2022-in-review )
Defelippe VM, van Thiel GJMW, Otte WM, et al. 2023 Toward responsible clinical n-of-1 strategies for rare diseases. Drug Discov. Today 28 103688
Duan D 2023 Duchenne muscular dystrophy gene therapy in 2023: status, perspective, and beyond. Hum. Gene Ther. 34 345–349
Haffner ME 2016 History of orphan drug regulation-united states and beyond. Clin. Pharmacol. Ther. 100 342–343
Jayasundara K, Hollis A, Krahn M, et al. 2019 Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J. Rare Dis. 14 12
Kacetl J, Marešová P, Maskuriy R, et al. 2020 Ethical questions linked to rare diseases and orphan drugs - a systematic review. Risk Manag. Healthc. Policy 13 2125–2148
Liao Z, Qian M, Kronish IM, et al. 2023 Analysis of N-of-1 trials using Bayesian distributed lag model with autocorrelated errors. Stat. Med. 42 2044–2060
Marks P and Wilson JM 2023 How can the FDA improve processes for rare diseases? 2023 RARE Drug Development Symposium; Global Genes (https://globalgenes.org/blog/how-can-the-fda-improve-processes-for-rare-diseases-2023-rare-drug-development-symposium/)
Maynard K, Browning-McNee LA, Nizar N, et al. 2023 The regulatory landscape: pathways, end points, and clinical trials. 2023 RARE Drug Development Symposium; Global Genes. (https://globalgenes.org/blog/the-regulatory-landscape-pathways-end-points-and-clinical-trials-2023-rare-drug-development-symposium/)
Ministry of Health 2016 The Right of Persons with Disabilities Act, 2016 (https://www.indiacode.nic.in/bitstream/123456789/15939/1/the_rights_of_persons_with_disabilities_act%2C_2016.pdf)
Ministry of Health 2021 National Policy for Treatment of Rare Diseases (NPTRD). (https://main.mohfw.gov.in/sites/default/files/Final%20NPRD%2C%202021.pdf)
Ministry of Health and Family Welfare 2023 Digital portal for crowdfunding & voluntary donations for patients of rare diseases (https://rarediseases.mohfw.gov.in/Hospital_Treating_Rare_Diseases)
Ministry of Social Justice and Empowerment 2000 The Rehabilitation Council of India (Amendment) Act, 2000. The Gazette of India (https://rehabcouncil.nic.in/sites/default/files/rciact-amendment-2000.pdf)
Mishra M and Satija B 2022 Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal (Reuters) (https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/)
Mulero A 2023 CBER to launch operation warp speed for rare diseases by year’s end (Biospace) (https://www.biospace.com/article/cber-to-launch-operation-warp-speed-for-rare-diseases-by-year-s-end/)
Müller AR, Brands M, van de Ven PM, et al. 2021 Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: The power of 1. Neurology 96 529–540
Nikles J and McDonald S 2021 N-of-1 trials in healthcare. Healthcare 9 330
Orphan-Drug-Approvals 2023 Search orphan drug designation approvals (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/)
Pingali V and Das N 2021 Rare diseases require support too. Vikalpa 46 129–134
Rajasimha HK, Shirol PB, Ramamoorthy P, et al. 2014 Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases’ community. Genet Res. 96 e009
Ramanan S and Dave SK 2021 Orphan drug development for rare diseases (Regulatory Affairs Professionals Society) (https://www.raps.org/products/orphan-drug-development-for-rare-diseases-e-book)
Rotenstreich Y, Harats D, Shaish A, et al. 2010 Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis-β-carotene. Br. J. Ophthalmol. 94 616–621
Scholl HP, Moore AT, Koenekoop RK, et al. 2015 Safety and proof-of-concept study of oral QLT091001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein (RPE65) or lecithin:retinol acyltransferase (LRAT). PLoS One 10 e0143846
Smith LD and Kingsmore SF 2014 N-of-1 genomic medicine for the rare pediatric genetic diseases. Expert Opin. Orphan Drugs 2 1279–1290
Srivastava G and Wislow A 2023 Orphan drugs: Understanding the FDA approval process (Academic Enterpreneurship for Medial and Health Scientists) (https://academicentrepreneurship.pubpub.org/pub/einr3b30/release/3#summary)
Synofzik M, van Roon-Mom WMC, Marckmann G, et al. 2022 Preparing N-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: Genetic, regulatory, and ethical perspectives. Nucleic Acid Ther. 32 83–94
US-FDA 2022 Medical products for rare diseases and conditions (U.S. Food and Drug Administration) (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions)
US-FDA 2023a Cellular, Tissue, and Gene Therapies Advisory Committee May 12, 2023 meeting announcement (U.S. Food and Drug Administration) (https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-may-12-2023-meeting-announcement-05122023)
US-FDA 2023b Rare diseases at FDA (U.S. Food and Drug Administration) (https://www.fda.gov/patients/rare-diseases-fda)
US-FDA 2023c Rare diseases at the FDA (U.S. Food and Drug Administration) (https://www.fda.gov/patients/rare-diseases-fda)
US-FDA 2023d Rare diseases: common issues in drug development guidance for industry (U.S. Food and Drug Administration) (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-common-issues-drug-development-guidance-industry)
Vashishta L, Bapat P, Bhattacharya Y, et al. 2023 A survey of rare disease awareness among healthcare professionals and researchers in India. J. Biosci. 48 37
Zarbin MA and Novack G 2021 N-of-1 clinical trials: A scientific approach to personalized medicine for patients with rare retinal diseases such as retinitis pigmentosa. J. Ocul. Pharmacol. Ther. 37 495–501
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: Alok Bhattacharya
This article is part of the Topical Collection: The Rare Genetic Disease Research Landscape in India.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chirmule, N., Feng, H., Cyril, E. et al. Orphan drug development: Challenges, regulation, and success stories. J Biosci 49, 30 (2024). https://doi.org/10.1007/s12038-024-00425-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12038-024-00425-y